Intellectual Property - August 24, 2022
Ultimovacs strengthens IP portfolio
Ultimovacs has announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for the company’s US application for a patent covering methods for eliciting a T cell immune response with the UV1 universal cancer vaccine. Subject to grant formalities, the company expects that the patent will issue with a […]
Intellectual Property - August 5, 2022
Valo Therapeutics acquires PeptiCHIP technology
Valo Therapeutics has announced the exclusive licensing of intellectual property rights (IPR) from the University of Helsinki for the institution’s innovative PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. This is a strategically important addition for the company as it will […]
Biotech Business - June 2, 2022
Asgard Therapeutics granted US patent
Asgard Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Asgard’s foundational patent related to the method of reprogramming cells towards the dendritic cell fate. The patent provides protection and market exclusivity of products based in the cell reprogramming method until 2038, such as Asgard’s innovative cancer immunotherapies, describes the […]
Intellectual Property - May 25, 2022
Ilya Pharma extends global patent coverage
Ilya Pharma has announced that the Indian Patent Office (IPO) has issued the Company Patent titled “Methods for Wound Healing”. The patent covers the general use of a plasmid capable of expressing the protein CXCL12 in L. reuteri. The modified bacteria may be used for treatment of both mucosal and cutaneous wounds in humans and […]
Intellectual Property - May 11, 2022
BioArctic receives new drug substance patent in the US
BioArctic has announced that the US Patent and Trademark Office (USPTO) has granted a new drug substance patent for the antibody ABBV-0805, invented by BioArctic as a potential treatment of Parkinson’s disease. The patent will take effect on May 24, 2022, and expire in 2041, with the possibility of a patent term extension up until […]
Intellectual Property - May 2, 2022
Spago Nanomedical receives extended patent protection in USA
Spago Nanomedical has received notice from the United States Patent and Trademark Office (USPTO) that it intends to grant the company’s patent application including a critical component of the SpagoPix candidate drug SN132D. The patent will be granted following confirmation of Spago Nanomedical and payment of applicable fees, states the company. The granted patent is […]
